It has been recently revealed that the drug for diabetes which was under trial by the FDA is not passed for authenticity for now. They are of the view that there is need for more research and data on the drug, before they can approve it. The name of the drug is dapagliflozin and the FDA is of the view that there is need to prove its worth according to safety, before it can be approved.

Researchers of Bristol-Myers Squibb have developed a new drug for the treatment of cancer. The drug is known as Ipilimumab and besides skin cancer, it is claimed to be successful on prostate, liver, lung and brain tumors.

The financial results of the first quarter of 2011 of Bristol-Myers Squibb are out and reports have definitely highlighted positive signs of strong growth and progress towards the business goals of the company.

The recent data published by the staff in clinical research jobs at Pfizer and Bristol-Myers Squibb (BMS) is reported to have shown an explicit comparison of the benefits posed by the venous thromboembolism (VTE) drug apixaban compared to a leading rival drug.

The share prices of Bristol-Myers Squibb Co's were up by 2.6% higher even in the thin Frankfurt market. There were reports that its experimental drug ipilimumab significantly helped increase survival rates in patients with skin cancer.

Bristol-Myers Squibb Co. announced late Tuesday that company veteran Lamberto Andreotti, the drug maker's President and Chief Operating Officer, will become Chief Executive on May 4, a step that should continue the company's transformation into a midsize, pure-play drug manufacture.

Bristol-Myers Squibb Co., the New York-based drug company, lowered its current year's outlook on the back of the Mead deal and the spin-off involved in it.

AstraZeneca PLC and Bristol-Myers Squibb Co. said that dapagliflozin, their new diabetes drug has achieved its target in a late-stage clinical study by helping to decrease blood sugar levels.

The once-daily treatment drug for Type 2 diabetes, Onglyza - generically called saxagliptin - has been approved by the US Food and Drug Administration (FDA). Onglyza has been manufactured by Bristol-Myers Squibb Co., which will also be marketing the drug, along with AstraZeneca PLC.

The reports of the finding of the Food and Drug Administration - relating to trace amounts of melamine present in US-made baby formula - have caused alarm among parents, even as the agency claimed that the low level po